#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	)																
1. Name and Address of Reporting Person * DOBMEIER ERIC				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)XDirector10% Owner						
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 06/08/2021									Officer (give	e title below)	Othe	er (specify belo	w)	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person  Form filed by More than One Reporting Person							
SOUTH SAN FRANCISCO, CA 94080 (City) (State) (Zip)																		
		(State)		1												ficially Owner		
1.Title of Se (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Dat any (Month/Day/Y		ate, if (				4. Securities Acquire (A) or Disposed of ( (Instr. 3, 4 and 5)		f (D) Owned Fo					Ownership Form:	7. Nature of Indirect Beneficial Ownership
				(WOIIII)	<i>Day</i> /	( i cai)	Cod	e V	A	mount	(A) or (D)	Price	(IIISU	. 3 and 4)			r Indirect (I) Instr. 4)	•
Common	Stock		06/08/2021				A		11	,000	A	\$ 0	39,0	000			D	
			Table II -					in th disp uired, D	nis fo plays ispos	orm are a curr	e not re rently v	equired valid O ficially	d to r	espond control n	unless the	ion contain form	ed SEC	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	ate, if Transaction of Derivative Expiration Date Code Securities (Month/Day/Year)		7. Title and Amount of Underlying Deriv Securities Securities				Owned Following Reported Transaction(	Owners Form of Derivati Security Direct (I or Indirects)	Beneficia Ownershi (Instr. 4)						
				Code	V	(A)	(D)	Date Exercis	sable	Expira Date	tion	Title		Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Non- Qualified Stock Option (Right to Buy)	\$ 13.80	06/08/2021		A		17,500	)	<u>(2</u>	)	06/07	//2031	Comi Sto		17,500	\$ 0	17,500	D	

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
DOBMEIER ERIC C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X					

## **Signatures**

/s/ David Tucker, Attorney-in-Fact	06/09/2021			
**Signature of Reporting Person	Date			

#### **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
- (2) The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.